Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received an average rating of “Buy” from the eight ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $10.75.
A number of research firms have weighed in on NEO. ValuEngine raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. BidaskClub lowered shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. BTIG Research reissued a “buy” rating and issued a $11.00 target price on shares of NeoGenomics in a research note on Sunday, May 28th. Finally, Cantor Fitzgerald set a $11.00 price target on shares of NeoGenomics and gave the stock a “buy” rating in a report on Saturday, May 27th.
Shares of NeoGenomics (NASDAQ:NEO) traded up 0.11% during trading on Monday, hitting $9.32. The stock had a trading volume of 150,157 shares. The stock has a 50 day moving average of $8.89 and a 200 day moving average of $8.16. NeoGenomics has a 12 month low of $6.90 and a 12 month high of $9.93. The company’s market cap is $738.49 million.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $0.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.03. The firm had revenue of $66.09 million for the quarter, compared to analyst estimates of $62.95 million. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.02%. NeoGenomics’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company posted $0.04 EPS. Equities analysts forecast that NeoGenomics will post $0.18 EPS for the current fiscal year.
In other NeoGenomics news, Director Alison L. Hannah purchased 20,000 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was bought at an average price of $9.19 per share, with a total value of $183,800.00. Following the transaction, the director now directly owns 38,782 shares of the company’s stock, valued at approximately $356,406.58. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steven A. Ross sold 70,833 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $7.76, for a total transaction of $549,664.08. Following the completion of the transaction, the insider now directly owns 4,500 shares of the company’s stock, valued at approximately $34,920. The disclosure for this sale can be found here. Insiders sold a total of 84,890 shares of company stock valued at $665,707 in the last quarter. 12.20% of the stock is owned by insiders.
Several large investors have recently added to or reduced their stakes in the company. Suntrust Banks Inc. boosted its stake in NeoGenomics by 0.6% in the first quarter. Suntrust Banks Inc. now owns 31,617 shares of the medical research company’s stock valued at $249,000 after buying an additional 184 shares during the period. Teachers Advisors LLC boosted its stake in NeoGenomics by 0.4% in the fourth quarter. Teachers Advisors LLC now owns 93,314 shares of the medical research company’s stock valued at $800,000 after buying an additional 396 shares during the period. Renaissance Group LLC boosted its stake in NeoGenomics by 1.1% in the first quarter. Renaissance Group LLC now owns 41,646 shares of the medical research company’s stock valued at $329,000 after buying an additional 470 shares during the period. Principal Financial Group Inc. boosted its stake in NeoGenomics by 2.5% in the first quarter. Principal Financial Group Inc. now owns 22,164 shares of the medical research company’s stock valued at $175,000 after buying an additional 545 shares during the period. Finally, ClariVest Asset Management LLC boosted its stake in NeoGenomics by 1.0% in the first quarter. ClariVest Asset Management LLC now owns 89,000 shares of the medical research company’s stock valued at $701,000 after buying an additional 900 shares during the period. 78.31% of the stock is owned by institutional investors and hedge funds.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.